Breath Predict Ltd
Breath Predict Ltd develops Exhale-Dx, a non-invasive AI-powered breath analysis platform for asthma diagnosis, attack prediction and remote monitoring, serving GP clinics, NHS systems, pharmaceutical companies, CROs and asthma patients from clinic to home.
- Company typePrivate
- Founded2025
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Breath Predict Ltd does
Breath Predict Ltd is a private, London-based company developing Exhale-Dx, a non-invasive, point-of-care breath analysis platform for asthma diagnosis, attack prediction, and respiratory monitoring. The device captures 13 breath parameters, including amplitude, variability, and chemical composition, and applies a proprietary deep learning framework trained on multi-site clinical breath data to identify asthma patterns and calculate attack probability. The company reports results in under 60 seconds, 93% diagnostic accuracy in a published 195-patient pilot, and attack prediction up to three days in advance; a separate 194-patient feasibility-study count is also reported, creating a minor patient-count discrepancy.
The intended users include GP clinics and primary-care providers, asthma patients using home monitoring, NHS systems, pharmaceutical companies, and contract research organizations. The company uses a direct, sales-led and enterprise-focused model, targeting GP clinics and NHS systems while using CRO and pharmaceutical partnerships for clinical development. Monetization is structured around Exhale-Dx hardware sales, recurring remote-monitoring services, and clinical-trial support services, but no prices, paid contracts, customers, or revenue are disclosed. UKCA certification and FDA submission remain in progress, and two accepted international patent applications are reported to protect the breath parameters and AI framework.
Breath Predict Ltd firmographics
Firmographics- Name
- Breath Predict Ltd
- Legal name
- Breath Predict Ltd
- Website
- https://breathpredict.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Breath Predict Ltd develops Exhale-Dx, a non-invasive AI-powered breath analysis platform for asthma diagnosis, attack prediction and remote monitoring, serving GP clinics, NHS systems, pharmaceutical companies, CROs and asthma patients from clinic to home.
- Ownership category
- akta.pro rank
Breath Predict Ltd industry classification
Industry- Product category
- Respiratory Diagnostic Devices
- NAICS
- Software Publishers (5132)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)
- akta.pro secondary industry
- Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB)
Keywords
Where Breath Predict Ltd is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Breath Predict Ltd business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Exhale-Dx Device Sales: Sale of the Exhale-Dx medical device for clinical and home use in asthma diagnosis and monitoring.
- Remote Monitoring Services: Continuous respiratory monitoring services from GP clinic to home, enabling proactive and preventive asthma care through the connected platform.
- Clinical Trial Services: Partnership with pharma companies and CROs to support clinical trials with breath analysis technology for respiratory drug development and validation.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels2 records
Breath Predict Ltd product offering
Product offeringCore offering
Breath Predict develops and sells Exhale-Dx®, an AI-powered breath analysis medical device that captures 13 distinct breath parameters in real time and uses a proprietary deep learning framework to diagnose asthma and predict asthma attacks up to 3 days in advance, delivering clinical-grade results in under 60 seconds at the point of care. The platform enables continuous respiratory monitoring from GP clinic to home and is offered to NHS healthcare systems, GP clinics, pharmaceutical companies, and CROs.
Product overview
Breath Predict Ltd offers a single unified AI-powered breath testing platform called Exhale-Dx™. This core product analyzes breath biomarkers using a proprietary deep learning framework trained on clinical data to provide asthma diagnosis and attack prediction up to 3 days in advance. The device is designed for use from GP clinic to home, supporting continuous respiratory monitoring with results delivered in under 60 seconds.
Differentiator
Problem solved
Functional benefit
Brands
- Exhale-Dx®: AI-powered breath testing device and platform for asthma diagnosis and remote monitoring, delivering clinical-grade results in under 60 seconds.
Products and services
- Exhale-Dx® Breath Analysis Device AI-powered breath testing device that captures 13 distinct breath parameters in real time and uses a proprietary deep learning framework to deliver clinical-grade asthma diagnostics in under 60 seconds. Designed for use from GP clinic to home with no lab setup or trained operator required. For healthcare providers (GP clinics, NHS systems) and asthma patients for point-of-care diagnosis and continuous monitoring.
- Remote Monitoring Services Continuous respiratory monitoring service delivered through the connected Exhale-Dx platform, enabling proactive and preventive asthma care from GP clinic to home as a recurring subscription offering.
- Clinical Trial Services Partnership service offering Exhale-Dx breath analysis technology to pharmaceutical companies and CROs for respiratory drug development, clinical trial endpoints, and efficacy monitoring.
Quantifiable outcome
- 93% diagnostic accuracy validated in published clinical pilot study of 195 patients
- +4 more outcomes
Companies that use Breath Predict Ltd
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Breath Predict Ltd technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Breath Predict Ltd partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Leading CROs and Pharma PartnerscoreActive partnerships with leading Contract Research Organizations (CROs) and pharmaceutical companies for respiratory drug clinical trials and development support. The company is pursuing these partnerships to expand clinical validation and commercial deployment of the Exhale-Dx platform in drug development and clinical research applications.
Scale indicators7 records
Recent moves4 records
Expansion highlights5 records
Breath Predict Ltd competitors and assessment
Company assessmentEmerging players
- Cosinuss GmbH: Cosinuss develops in-ear wearable vital sign sensors including respiratory monitoring. It is an emerging player in connected respiratory monitoring with potential overlap on the home-use remote monitoring segment where Breath Predict's Exhale-Dx is positioned.
- Adherium: Adherium develops connected inhaler sensors and remote respiratory monitoring for asthma and COPD patients. It competes in the asthma remote monitoring segment that Breath Predict's subscription service targets, though Adherium focuses on adherence rather than breath biomarker analysis.
- Respiri: Respiri (formerly iSonea) develops wheeze and cough detection technology for asthma and COPD monitoring using connected devices and AI. It overlaps with Breath Predict's remote respiratory monitoring and predictive use case, though Respiri focuses on acoustic rather than chemical biomarkers.
- ZEPHYRx: ZEPHYRx develops remote respiratory monitoring platforms integrating connected spirometers and other devices for clinical trials and chronic care management. It overlaps with Breath Predict's pharma/CRO clinical trial services and remote monitoring subscription revenue streams in the asthma and COPD population.
Broad incumbents
- MGC Diagnostics: MGC Diagnostics is a US-based manufacturer of pulmonary function testing (PFT) equipment and cardiopulmonary diagnostics. It is a broad incumbent in the respiratory diagnostics space where Breath Predict also operates, though MGC focuses on hospital-based PFT rather than point-of-care AI breath analysis.
- Bosch Healthcare Solutions: Bosch Healthcare Solutions is the medical technology arm of Bosch focused on breath analysis and sensor-based diagnostics. It is an established player in breath analysis R&D for clinical applications, comparable as a large adjacent technology provider in the same category Breath Predict competes in.
- Propeller Health (ResMed): Propeller Health, owned by ResMed, is a leading digital respiratory health platform for asthma and COPD inhaler adherence and remote monitoring. It competes with Breath Predict's remote monitoring subscription stream in the asthma patient population, though it does not perform breath-based diagnostics.
Direct peers
- Owlstone Medical: Owlstone Medical is a UK-based breath biopsy company developing breath analysis tests for respiratory disease and cancer, named by Breath Predict as a direct competitor. Both companies analyze exhaled breath biomarkers for clinical diagnostics, with Owlstone focused more on disease detection and Breath Predict on asthma attack prediction.
- Breathomix: Breathomix is a Dutch company developing electronic nose (eNose) breath analysis technology for respiratory and metabolic disease diagnosis, explicitly named on Breath Predict's competitive comparison table. Both companies use AI to interpret complex breath biomarker signatures for clinical respiratory diagnostics.
- NIOX Group (formerly Circassia): NIOX makes the FeNO (fractional exhaled nitric oxide) measurement device used widely in asthma diagnosis. FeNO is explicitly cited as incumbent technology that Exhale-Dx aims to displace with its faster, AI-powered, point-of-care approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Breath Predict Ltd social profiles
Digital presenceBreath Predict Ltd compliance and trust
Trust signalCompliance2 records
Breath Predict Ltd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Breath Predict Ltd leadership team
Management profileNumber of profiles
Breath Predict Ltd funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Breath Predict Ltd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Breath Predict Ltd
What does Breath Predict Ltd do?
Breath Predict develops and sells Exhale-Dx®, an AI-powered breath analysis medical device that captures 13 distinct breath parameters in real time and uses a proprietary deep learning framework to diagnose asthma and predict asthma attacks up to 3 days in advance, delivering clinical-grade results in under 60 seconds at the point of care. The platform enables continuous respiratory monitoring from GP clinic to home and is offered to NHS healthcare systems, GP clinics, pharmaceutical companies, and CROs.
Is Breath Predict Ltd a public or private company?
Breath Predict Ltd is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Breath Predict Ltd founded?
Breath Predict Ltd was founded in 2025. It employs 1 to 10 people.
Where is Breath Predict Ltd based?
Breath Predict Ltd is headquartered in London, United Kingdom, in the Europe region.
How does Breath Predict Ltd make money?
Three revenue lines are on record. Exhale-Dx Device Sales are the primary driver. The others are remote Monitoring Services and clinical Trial Services.
Who are Breath Predict Ltd's main competitors?
Emerging players on record are Cosinuss GmbH, Adherium, Respiri and ZEPHYRx. Broad incumbents are MGC Diagnostics, Bosch Healthcare Solutions and Propeller Health (ResMed). Direct peers are Owlstone Medical, Breathomix and NIOX Group (formerly Circassia).
Does Breath Predict Ltd have an API?
No public API is recorded for Breath Predict Ltd.
What industry is Breath Predict Ltd in?
Breath Predict Ltd's product category is Respiratory Diagnostic Devices. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry), with a secondary code of HLALAFAB, Respiratory & Sleep RPM (COPD, asthma, sleep apnea). Its NAICS code is 5132 and its SIC code is 2835.